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CASE PRESENTATION
A 26-year-old female was found to have renal
insufficiency on routine laboratory studies. She denied
gross hematuria, edema, or oliguria. She had no history of
diabetes, hypertension, arthritis, urinary tract infections,
or nephrolithiasis. Her only medication was an oral
contraceptive (Lo/Ovral). On physical examination, the
patient had blood pressure of 120/66 mm Hg, heart rate of
70 per min, and weight of 146 lb. Cardiovascular,
pulmonary, and abdominal examinations were
unremarkable. There was no evidence of rash or edema.
Laboratory examination showed a total leukocyte count of
7000/mm3 (normal range 4000–9000/mm3), hematocrit
39.8% (normal range 33.0–45.0%), platelet count
242 109/l (normal range 140–360 109/l), 24-h urine
protein 70 mg, serum albumin 4.3 g per 100 ml (43 g/L)
(normal range 3.2–5.2 g per 100 ml (32–52 g/L)), serum
creatinine 1.6 mg per 100 ml (141mmol/L), creatinine
clearance 71 ml/min, and serum cholesterol 222 mg per
100 ml (5.74 mmol/L). Serum electrolytes were normal
including sodium, potassium, glucose, bicarbonate, and
calcium. The patient had normal serum complements. The
following serologies were negative: antinuclear antibody,
antidouble-stranded DNA antibody, antineutrophil
cytoplasmic antibody, hepatitis B surface antigen, and
hepatitis C antibody. Urinalysis showed specific gravity
1.010, pH 5.0 and was negative for protein, blood, glucose,
and nitrite. Microscopic examination of the urine revealed
0–5 white blood cells per high-power field, no red blood
cells, and no hyaline or granular casts. Renal ultrasound
showed normal-sized kidneys with normal echogenicity
and no hydronephrosis, masses, or cysts. A renal biopsy
was performed.
RENAL BIOPSY FINDINGS
Light microscopic evaluation revealed one core of renal
cortex and medulla with overlying capsule. A total of 13
glomeruli were identified, three of which were globally
sclerotic. Glomeruli appeared histologically unremarkable.
Approximately 30% of the cortex showed patchy tubular
atrophy and interstitial fibrosis accompanied by a sparse
interstitial infiltrate of mononuclear leukocytes (Figure 1).
In these areas, the tubules exhibited focal epithelial
simplification with enlarged reparative nuclei and prominent
nucleoli. On high-power examination, distal tubules and
thick ascending limbs of the Henle (TALH) contained focal
intracytoplasmic irregular pale inclusions with a lamellated
texture that displaced the nucleus. The intracytoplasmic
inclusions were weakly eosinophilic, weakly periodic
acid-Sciff stain-positive, trichrome blue, and non-refractile
under polarized light (Figure 2). No tubular or glomerular
cysts, tubulitis, or interstitial eosinophils were identified.
Vessels appeared unremarkable. Immunofluorescence stain-
ing was negative for IgG, IgA, C1q, albumin, fibrinogen,
kappa-, and lambda-light chains in glomeruli and tubules.
There was a nonspecific 1þ granular mesangial positivity for
IgM and C3.
On ultrastructural evaluation, distal tubules and TALH
contained intracytoplasmic inclusions composed of stacked
lamellar structures that appeared to represent hyperplastic
bundles of the endoplasmic reticulum (ER) (Figures 3 and 4).
Between the lamellae of membrane material, there were
accumulations of granular moderately electron-dense mate-
rial, producing focal large aggregates that distended the
ER. No intralysosomal inclusions were seen. Some of
the distal tubular epithelial cells were undergoing apoptosis.
There was focal thickening and lamellation of tubular
basement membranes in the involved tubules. No intra-
cytoplasmic inclusions were identified involving other
cell types and no extracellular inclusions or immune-
type electron-dense deposits were seen. Glomeruli were
unremarkable; no electron-dense deposits, endothelial
tubuloreticular inclusions, or significant foot process
effacement were identified. Proximal tubules appeared
unremarkable.
The findings were interpreted as a chronic tubulo-
interstitial nephropathy with distal tubular intracytoplasmic
inclusions, suggestive of a storage disease.
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Clinical follow-up
Following the renal biopsy, additional laboratory studies were
performed. The patient was found to have an elevated serum
uric acid of 9.4 mg per 100 ml (559 mmol/L) (normal range
2.4–5.7 mg per 100 ml (143–339 mmol/L)) and depressed
serum phosphorus of 2.5 mg per 100 ml (0.81 mmol/L)
(normal range 2.6–4.5 mg per 100 ml (0.84–1.45 mmol/L)).
Random urine sodium, phosphorus, and glucose levels were
normal. Over the next several months, the patient’s 31-year-
old sister was found to have gout and an elevated serum
creatinine of 1.4 mg per 100 ml (124 mmol/L).
The clinical differential diagnosis of familial renal failure
and hyperuricemia included familial juvenile hyperuricemic
nephropathy (FJHN), medullary cystic kidney disease type 2
(MCKD2), and partial hypoxanthine–guanine phosphoribosyl-
transferase deficiency, an X-linked disorder that results in
the overproduction of uric acid. The patient’s female gender
and the absence of neurological symptoms, history of
nephrolithiasis, or urate granulomas on renal biopsy argued
against partial hypoxanthine–guanine phosphoribosyltrans-
ferase deficiency. The renal biopsy findings were consistent
with FJHN or MCKD2. The patient and her sister were tested
Figure 1 | On low-power view, the cortex displays focal patchy
tubular atrophy and interstitial fibrosis, with minimal interstitial
inflammation. No tubulitis is seen. The glomerulus is unremarkable
(hematoxylin and eosin, original magnification  200).
Figure 2 | On high-power, distal tubular cells contain focal
intracytoplasmic inclusions of lamellated trichrome blue material
(arrows) that contrasts with the red staining cytoplasm (Masson
trichrome, original magnification  600).
Figure 3 | A representative distal tubular profile shows a cell at
center containing dilated cisternae of the ER in which there is
accumulation of granular, moderately electron dense storage
material (arrow). The tubular basement membrane appears
thickened and lamellated (electron micrograph, original
magnification  4000).
Figure 4 | On high power, distal tubular cells contain hyperplastic
bundles of the ER (arrow) with few intervening mitochondria
alternating with areas of dilated ER containing storage material
(arrowhead) (electron micrograph, original magnification
 6000).
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for uromodulin (UMOD) mutations by PCR amplification of
genomic DNA and bidirectional automated DNA sequencing
of exons 4 and 5 in the coding region of the UMOD gene
(testing was performed by Athena Diagnostics Inc., Worce-
ster, MA, USA). The two sisters were found to have an
identical missense mutation in nucleotide 808 (guanine to
thymine), resulting in exchange of glycine for cysteine (codon
position 270), consistent with UMOD-associated kidney
disease.
Subsequently, the patient’s 17-year-old brother was found
to have a serum creatinine of 1.8 mg per 100 ml (159 mmol/L)
and hyperuricemia, and a 17-year-old female cousin
presented with gout, a uric acid level of 410 mg per
100 ml (595 mmol/L), and normal renal function. All of the
affected family members were treated with allopurinol, and
there were no subsequent flares of gout. Four years after the
renal biopsy, the patient has a serum creatinine of 1.8 mg per
100 ml (159 mmol/L) and uric acid of 4.2 mg per 100 ml
(250 mmol/L). She remains on allopurinol therapy.
Immunohistochemical detection of UMOD
Immunohistochemical staining for UMOD was performed
on formalin-fixed, paraffin-embedded tissue. Non-neoplastic
renal parenchyma from a nephrectomy for renal tumor
served as a normal control. Briefly, sections were deparaffi-
nized, rehydrated, antigen-digested in citrate buffer, pH 6
(Code S1699; Dako, Carpinteria, CA, USA) using a steamer
for 45 min, quenched in 0.3% H2O2 in ethanol, and then
overlaid with monoclonal anti-human Tamm–Horsfall anti-
body (clone 10.32; Cedarane, Hornby, ON, Canada) diluted
1:1 000 000 for 30 min. Detection of the bound primary
antibody was achieved by incubation with a peroxidase-
labeled polymer conjugated to goat anti-mouse secondary
antibody (DakoCytomation EnVisionþ system, code K4000;
Dako) for 30 min, followed by incubation for 2 min in
diaminobenzidine.
The normal control case demonstrated diffuse homo-
genous cytoplasmic and apical positivity for UMOD in the
distribution of the TALH (Figure 5), as well as a strong
positivity in Tamm–Horsfall tubular casts. By contrast, the
test case exhibited more intensely staining dense, coarse
intracytoplasmic aggregates with a lamellar texture within the
cells of the TALH, corresponding to the intracellular
inclusions seen by light and electron microscopy (Figure 6).
There was reduced apical membrane staining and no cast
staining.
Final diagnosis
Familial juvenile hyperuricemic nephropathy (UMOD
storage disease).
DISCUSSION
FJHN and MCKD2 are rare primary tubulointerstitial
disorders with autosomal-dominant inheritance. They are
characterized clinically by chronic renal failure progressing to
end-stage renal disease, hyperuricemia and gout, and mildly
reduced urine concentrating ability. Histologically, there is
interstitial fibrosis, tubular atrophy, and tubular basement
membrane thickening and splitting. In 2002, Hart et al.1
identified four novel mutations in the UMOD gene in three
families with FJHN and in one family with MCKD2. Since
then, over 37 different heterozygous UMOD mutations have
been detected in patients with FJHN, MCKD2, or familial
glomerulocystic kidney disease from the United States,
Europe, and Japan.1–12 On the basis of the overlapping
clinical and pathologic features of FJHN and MCKD2 and the
recent discovery that both entities exhibit mutations in the
UMOD gene on chromosome 16p12, they can be considered
different phenotypes of the same disease. Some patients with
UMOD mutations have medullary cysts; these are most
frequently seen at autopsy and are inconsistent findings in
individuals and families with the disease. Glomerulocystic
kidney disease is a rare histopathologic entity characterized
by prominent cystic dilatation of Bowman’s space with
Figure 5 | Immunostain for UMOD in control kidney shows
homogeneous diffuse staining of cytoplasm and apical
membranes of TALH cells (original magnification  600).
Figure 6 | Immunostain of the patient’s biopsy shows focal
coarse, dense clusters of UMOD within TALH cells, corresponding
to the intracellular inclusions (original magnification  600).
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primitive glomerular tufts. A subset of glomerulocystic
kidney disease cases has an autosomal-dominant pattern of
inheritance and is associated with hyperuricemia/gout and
mutations in the UMOD gene.2,3 Mechanical obstruction of
the nephron owing to Tamm–Horsfall glycoprotein aggre-
gates during renal development is thought to promote
glomerulocyst formation. Because all three conditions share
mutations in the same gene, the collective term UMOD
storage disease (or UMOD-associated kidney disease)
recently has been proposed.8,13
In 2003, Bleyer et al.9 reported a large kindred with
hyperuricemia, gout, and renal insufficiency. A mutation in
the UMOD gene was identified in 39 family members. By the
age of 20 years, renal failure was present in 38 of the 39
individuals. Thirty-six patients had hyperuricemia. Males had
more severe and more frequent hyperuricemia and a faster
decline in renal function. Patients exhibited reduced
fractional excretion of uric acid and low urine osmolality.
Twenty-six percent of patients had enuresis, which often
persisted into teenage years.9 The clinical and pathologic
characteristics of patients with UMOD mutations are
summarized in Tables 1 and 2, respectively.
UMOD, also known as Tamm–Horsfall glycoprotein, is the
most abundant protein excreted in the urine in healthy
individuals. It is synthesized exclusively in the TALH and the
early distal convoluted tubule as a 640 amino-acid precursor
protein whose primary structure includes a 24 amino-acid
signal peptide at the N terminus followed by four calcium-
binding epidermal growth factor-like domains, a zona
pellucida-like domain, and one stretch of hydrophobic
amino acids at the C terminus.14 In the ER, the signal
peptide and hydrophobic portion are removed and the
glycosyl phosphatidylinositol anchor is added to the C
terminus. The membrane-bound glycoprotein is then sorted
to the apical cell membrane, where it attaches by its glycosyl
phosphatidylinositol anchor. The glycoprotein is released
into the tubular lumen via proteolytic cleavage of the glycosyl
phosphatidylinositol anchor from the C terminus.14,15
UMOD protein is rich in cysteine residues (48 of 616 amino
acids), allowing for the formation of interchain disulfide
bonds essential to maintain its tertiary structure. Most of the
UMOD mutations that have been identified are missense
mutations in exon 4, which encodes for the calcium-binding
epidermal growth factor-like domains. UMOD mutations
mainly alter cysteine amino acids. Missense mutations in
exon 5 and an in-frame deletion resulting in the loss of nine
amino acids have also been reported.1,3 Interestingly,
homozygosity for the dominant UMOD mutation has been
reported in a consanguineous Spanish family.10 Patients with
homozygous mutations did not have a lethal disease, but
developed earlier onset of hyperuricemia and more rapid
progression to end-stage renal disease than family members
with heterozygous mutations.10 UMOD mutations poten-
tially cause disruption of the molecule’s stable tertiary
structure, resulting in altered protein folding, accumulation
within the ER, and impaired trafficking.5,16,17 Massive
intracellular UMOD inclusions in distal tubular cells were
detected by immunohistochemistry in our patient and in
several patients reported by others.2,4,5,8,18 On electron
microscopy, the inclusions appear as abundant fibrillar or
granular storage material within bundles of ER, as seen in our
patient and three previously reported cases.2,5,8 The asso-
ciated ER hyperplasia seen in our case was also described by
Vylet’al et al.5
The biologic function of UMOD is incompletely under-
stood. Basic science experiments suggest that UMOD is an
important urinary defense factor against bacterial coloniza-
tion and stone formation. It prevents type 1-fimbriated
Escherichia coli from binding to the urothelial surface.19
UMOD gene knockout mice are susceptible to bladder
infection by type 1-fimbriated Escherichia coli and to calcium
oxalate crystal formation.20,21 However, the frequencies of
urinary tract infections and nephrolithiasis generally are not
increased in patients with UMOD mutations. How UMOD
mutations cause renal failure remains unclear. Accumulation
of the misfolded, mutated protein in the ER potentially
results in tubular cell dysfunction, apoptosis, and death,
leading to tubular atrophy and interstitial fibrosis.2,22,23 The
release of abnormal UMOD following cell death2,8 or
through basolateral secretion7 may induce an immune
response. Immunization of animals with Tamm–Horsfall
protein results in immune-mediated tubulointerstitial
nephritis with (in rat24) or without (in rabbit25) the
formation of granular deposits at the base of cells of TALH
and distal convoluted tubules. In patients with UMOD
mutations, however, there is no significant tubulitis, and no
granular immune complex-type tubulo-interstitial deposits
or interstitial UMOD deposits have been detected.
The cause of the hyperuricemia remains incompletely
understood. Most of urate reabsorption and secretion occur
Table 1 | Clinical characteristics of patients with UMOD
mutations
Autosomal-dominant mode of inheritance
Chronic renal insufficiency leading to ESRD in adulthood
Absent or minimal proteinuria
Inactive urine sediment with absence of hyaline casts
Hyperuricemia/gout
Fractional excretion of uric acid less than 5% in the setting of normal GFR
Impairment of urine concentration ability/enuresis
ESRD, end-stage renal disease; GFR, glomerular filteration rate; UMOD, uromodulin.
Table 2 | Pathologic findings in patients with UMOD
mutations
Tubular atrophy and interstitial fibrosis
Tubular basement membrane thickening and lamellation
Tubular or glomerular cysts (rare)
Fibrillar inclusions in the cells of TALH (appear as ER inclusions on electron
microscopy)
Dense intracellular UMOD inclusions in the cells of TALH (by
immunohistochemistry)
ER, endoplasmic reticulum; TALH, thick ascending limbs of the Henle; UMOD-
uromodulin.
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at the level of the proximal tubule. It has been suggested that
the intracellular UMOD overload impairs Na reabsorption by
the TALH, leading to defective urine concentrating capacity.
The resultant volume depletion may be compensated by
increased proximal tubular reabsorption of Na, which in turn
may promote heightened proximal tubular urate reabsorp-
tion and reduced secretion, similar to the mechanism
responsible for hyperuricemia in patients receiving loop
diuretics.8,26 Allopurinol treatment will correct hyperurice-
mia and prevent gouty attacks in the majority of patients.
Allopurinol therapy does not appear to prevent the renal
disease from progressing; although it is possible that
allopurinol slows progression, this has not been shown
conclusively.
In adults, the differential diagnosis of the tubular
inclusions seen in UMOD storage disease includes light-
chain Fanconi syndrome27 and adult Refsum’s disease.28,29 In
contrast to UMOD inclusions, the needle- or rod-shaped
intracytoplasmic crystals in light-chain Fanconi syndrome
accumulate in proximal tubules and characteristically stain
for k-light chain. Patients typically have evidence of plasma
cell dyscrasia and partial or complete Fanconi syndrome.27
Refsum’s disease is a rare autosomal-recessive disorder caused
by mutation in the gene for phytanoyl-CoA hydroxylase,
resulting in an abnormal accumulation of phytanic acid. It is
characterized clinically by retinitis pigmentosa, anosmia,
sensory neuropathy, hearing loss, ataxia, and cardiac
arrhythmias. Hyperuricemia is not a feature. Symptomatic
renal involvement is rare and includes mild renal insuffi-
ciency, proteinuria, and lipiduria.28 On light microscopy,
there is extensive vacuolization of podocytes and proximal
and distal tubular epithelia. On electron microscopy,
intracellular lipid vacuoles and inclusions composed of
quadrangular microtubules are seen in the distal convoluted
tubules and loop of Henle.28,29
The diagnosis of UMOD storage disease should be
suspected on clinical grounds and confirmed by genetic
testing without the need for renal biopsy. The current case
underscores the importance of careful family history taking.
If a renal biopsy is performed, the pathologist should be
familiar with the characteristic morphologic findings. In
patients with asymptomatic renal insufficiency, inactive urine
sediment and evidence of tubulo-interstitial nephropathy, the
finding of abnormal inclusions in the cells of TALH and distal
tubules by light microscopy or electron microscopy should
prompt testing for hyperuricemia and clinical evaluation of
other family members. Immunohistochemical staining for
UMOD is helpful to confirm the composition of the
inclusions. It is important to note that not all families with
UMOD mutation have UMOD inclusions1,4 and genetic
testing remains the definitive diagnostic tool. With early
diagnosis and treatment, clinical manifestations of gout can
be prevented or delayed. Because renal insufficiency may be
mild in young adult family members who are potential
donors, family members wishing to serve as transplant
donors need to be carefully screened and potentially undergo
UMOD mutational analysis for confirmation of unaffected
status.
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